Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Dent

Showing results (51-60 of 129) with videos related to

Pageof 13
Sort By:
Journal of the American College of Cardiology|May 28, 2021
Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art ReviewVijay U Rao, David J Reeves, Atul R Chugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancerStephen Chia, Susan Dent, Susan Ellard, et al.
JACC. Cardiooncology|October 10, 2022
Permissive Cardiotoxicity: The Clinical Crucible of Cardio-OncologyCharles Porter, Tariq U Azam, Divyanshu Mohananey, et al.
Journal of Oncology Practice|January 22, 2015
Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancerKatherine Enright, Eva Grunfeld, Lingsong Yun, et al.
Circulation. Cardiovascular Imaging|June 15, 2021
Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-UpSorin Giusca, Grigorios Korosoglou, Moritz Montenbruck, et al.
JAMA Oncology|November 13, 2015
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical TrialMark Clemons, Nathaniel Bouganim, Stephanie Smith, et al.
Cardio-Oncology (London, England)|July 27, 2025
The cardio-oncology multidisciplinary team: beyond the basicsJoshua D Bennetts, Trent D Williams, Craig J Beavers, et al.
Circulation|March 7, 2022
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart AssociationCraig J Beavers, Jo E Rodgers, Aaron J Bagnola, et al.
Breast Cancer Research and Treatment|June 25, 2009
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patientsOrit Freedman, Eitan Amir, George Dranitsaris, et al.
The Oncologist|August 5, 2010
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortiumSara K Taylor, Stephen Chia, Susan Dent, et al.
Pageof 13

Showing results (51-60 of 129) with videos related to

Sort By:
Pageof 13
Journal of the American College of Cardiology|May 28, 2021
Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art ReviewVijay U Rao, David J Reeves, Atul R Chugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancerStephen Chia, Susan Dent, Susan Ellard, et al.
JACC. Cardiooncology|October 10, 2022
Permissive Cardiotoxicity: The Clinical Crucible of Cardio-OncologyCharles Porter, Tariq U Azam, Divyanshu Mohananey, et al.
Journal of Oncology Practice|January 22, 2015
Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancerKatherine Enright, Eva Grunfeld, Lingsong Yun, et al.
Circulation. Cardiovascular Imaging|June 15, 2021
Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-UpSorin Giusca, Grigorios Korosoglou, Moritz Montenbruck, et al.
JAMA Oncology|November 13, 2015
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical TrialMark Clemons, Nathaniel Bouganim, Stephanie Smith, et al.
Cardio-Oncology (London, England)|July 27, 2025
The cardio-oncology multidisciplinary team: beyond the basicsJoshua D Bennetts, Trent D Williams, Craig J Beavers, et al.
Circulation|March 7, 2022
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart AssociationCraig J Beavers, Jo E Rodgers, Aaron J Bagnola, et al.
Breast Cancer Research and Treatment|June 25, 2009
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patientsOrit Freedman, Eitan Amir, George Dranitsaris, et al.
The Oncologist|August 5, 2010
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortiumSara K Taylor, Stephen Chia, Susan Dent, et al.
Pageof 13